Doctors say Pfizer’s Lyme disease vaccine trial results ‘encouraging’ after more than 70% efficacy shown
(NEW YORK) -- Earlier this week, pharmaceutical company Pfizer and its partner Valneva announced that an experimental Lyme disease vaccine showed more than 70% efficacy in late-stage clinical trials.The candidate, PF-07307405, showed 73.2% efficacy in reducing confirmed cases of Lyme disease cases after... Read More.
